Novartis' New Blood Pressure Weapon
BusinessWeek - Mar 7, 2007 In addition to the company's best-selling drug, Diovan, a hypertension drug ... patients Tekturna may ultimately reduce cardiovascular complications and the ...
|
|
|
|
|
|
|
|
CHAPTER 1 FORECAST ANALYSIS
$1,280.00 - DATAMONITOR PHARMACEUTICAL INTELLIGENCE... - Alacra Store - Mar 10, 2006 expected to show if early insulin treatment can reduce cardiovascular ... angiotensin receptor blocker (ARB) Diovan (valsartan) or nateglinide or the ...
|
|
|
|